Clik here to view.
グラコ、人間工学の性能認定を受けた初のエアスプレーガンを開発
ミネアポリス （ビジネスワイヤ） — 流体処理装置の大手メーカーであるグラコ(NYSE：GGG)は、人間工学の性能認証を取得した唯一の工業用エアスプレーガンであるStellair ACEとStellair™を発表しました。United States Ergonomicsによる高度なテストにより、手動加圧式スプレーが工業用塗装工の疲労の原因を減らし、生産性を向上させることが認められました。...
View ArticleClik here to view.
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer...
PALO ALTO, Calif. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the peer-reviewed journal Nature Medicine published results from the SCRUM-Japan GOZILA...
View ArticleClik here to view.
Axcelead DDP and Lilly Enter into Research and Collaboration Agreement
TOKYO Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced on September 5 that it has entered into a strategic research and collaboration agreement with...
View ArticleClik here to view.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the...
View ArticleClik here to view.
AIHA To Advance Global OEHS Through International Strategic Partnership,...
FALLS CHURCH, Va. AIHA, the association for scientists and professionals committed to preserving and ensuring occupational and environmental health and safety (OEHS), is embarking on two initiatives...
View ArticleClik here to view.
Conexus MedStaff Announces New Partnership with Fairplay for All Foundation,...
HOUSTON Conexus MedStaff and Fairplay for All Foundation announced a partnership to help children in the Philippines access education and live healthier lives. Funding of $2,500 from Conexus will...
View ArticleClik here to view.
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients...
TOKYO & BASKING RIDGE, N.J. Topline results from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to investigator’s choice of chemotherapy, which previously met...
View ArticleClik here to view.
New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease...
BARCELONA, Spain More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy...
View ArticleClik here to view.
Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid...
MALVERN, Pa. & TOKYO Fujirebio today announced that its wholly-owned subsidiary Fujirebio Diagnostics, Inc. has filed its Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic...
View ArticleClik here to view.
Merz Aesthetics宣布推出Ultherapy PRIME平台，作为下一代非手术皮肤提拉疗法
北卡罗来纳州罗利 (美国商业资讯)– 全球最大的专业医学美容企业Merz Aesthetics今天宣布推出Ultherapy PRIME——一种获得美国食品药品管理局(FDA)批准的无创医学美容疗法，可在一次疗程中提供真正个性化和持久的皮肤提拉效果，无需任何恢复期。1 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
メルツ・エステティックスが次世代の非外科的スキンリフティング治療「Ultherapy PRIMEプラットフォーム」のローンチを発表
ノースカロライナ州、ローリー （ビジネスワイヤ） — 世界最大の美容医療企業であるメルツ・エステティックスは、非侵襲的なFDA承認済み美容治療「Ultherapy PRIME」を発表しました。この治療はダウンタイムがなく、1回の施術で真にカスタマイズされた持続的なスキンリフトを提供します。1...
View ArticleClik here to view.
Fujirebio为Lumipulse® G pTau...
宾夕法尼亚州马尔文和东京 (美国商业资讯)– Fujirebio今天宣布，其全资子公司Fujirebio Diagnostics, Inc.已向美国食品药品管理局(FDA)提交其Lumipulse ® G pTau 217/β-淀粉样蛋白1-42血浆比值体外诊断(IVD)测试的监管文件。新的血浆测试有望成为美国首个有助于评估阿尔茨海默病(AD)的商用血液IVD测试。 Lumipulse G...
View ArticleClik here to view.
Promega Engineers New Enzyme to Significantly Reduce Stutter in Forensic DNA...
MADISON, Wis. A novel enzyme developed by research scientists at Promega Corporation will virtually eliminate confounding stutter artifacts in forensic DNA analysis. The reduced stutter polymerase...
View ArticleClik here to view.
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM...
IRVINE, Calif. Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable...
View ArticleClik here to view.
Kao Signs Memorandum of Understanding for Collaboration with Thailand’s C.P....
TOKYO On September 30, 2024, Kao Corporation (TOKYO:4452) (President and CEO: Yoshihiro Hasebe) signed a Memorandum of Understanding with Charoen Pokphand (C.P.) Group, Thailand’s leading...
View ArticleClik here to view.
癌症治疗：AOP Health研究靶向癌症干细胞的新方法
维也纳 (美国商业资讯)– AOP Orphan Pharmaceuticals GmbH (AOP Health) 与Leukos Biotech的合作迈向了一个重要的里程碑。SERONCO-1一期临床试验纳入首例患者，该试验旨在研究一种具有新颖独特作用机制（同类首创）的物质。该候选药物正在实体瘤和淋巴瘤患者中进行研究。AOP...
View ArticleClik here to view.
がん治療：AOPヘルス、がん幹細胞を標的とした新たなアプローチを研究
ウィーン （ビジネスワイヤ） — AOP Orphan Pharmaceuticals GmbH（AOPヘルス）はLeukos...
View ArticleClik here to view.
CAI Appoints Sheena Dempsey as Chief Executive Officer
INDIANAPOLIS CAI, a global professional services firm and trailblazer in operational readiness and excellence, today announced Sheena Dempsey as Chief Executive Officer (CEO). Dempsey is a widely...
View ArticleClik here to view.
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic...
FOSTER CITY, Calif. Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make...
View ArticleClik here to view.
Orum Therapeutics Submits Registration Statement for KOSDAQ Listing
DAEJEON, South Korea & BOSTON Orum Therapeutics (“Orum” or the “Company”), a biopharmaceutical company pioneering the field of degrader-antibody conjugates (DACs) based on its Dual-Precision...
View Article